Cargando…

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

Anti-vascular effects of the novel Vinca alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation Vinca. Administration of the maximum tolerated dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Holwell, S E, Hill, B T, Bibby, M C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363703/
https://www.ncbi.nlm.nih.gov/pubmed/11161390
http://dx.doi.org/10.1054/bjoc.2000.1587
_version_ 1782153770714529792
author Holwell, S E
Hill, B T
Bibby, M C
author_facet Holwell, S E
Hill, B T
Bibby, M C
author_sort Holwell, S E
collection PubMed
description Anti-vascular effects of the novel Vinca alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation Vinca. Administration of the maximum tolerated dose of either vinflunine (50 mg kg(−1)) or vinorelbine (8 mg kg(−1)) resulted in significant tumour growth delay with subsequent histological analysis revealing substantial haemorrhagic necrosis. This suggested possible anti-vascular effects and these were confirmed by Hoechst 33342 perfusion studies. Vinflunine, currently undergoing Phase I trials in Europe, was found to be at least as effective as the clinically active vincristine and vinorelbine in this model and, remarkably, produced anti-vascular effects at doses much lower than the maximum tolerated dose. Although vinflunine caused apoptosis in HUVEC monolayer cultures this event did not occur within the first 8 hours of exposure whereas vascular shutdown in vivo was observed within the first 4 hours. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2363703
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23637032009-09-10 Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model Holwell, S E Hill, B T Bibby, M C Br J Cancer Regular Article Anti-vascular effects of the novel Vinca alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation Vinca. Administration of the maximum tolerated dose of either vinflunine (50 mg kg(−1)) or vinorelbine (8 mg kg(−1)) resulted in significant tumour growth delay with subsequent histological analysis revealing substantial haemorrhagic necrosis. This suggested possible anti-vascular effects and these were confirmed by Hoechst 33342 perfusion studies. Vinflunine, currently undergoing Phase I trials in Europe, was found to be at least as effective as the clinically active vincristine and vinorelbine in this model and, remarkably, produced anti-vascular effects at doses much lower than the maximum tolerated dose. Although vinflunine caused apoptosis in HUVEC monolayer cultures this event did not occur within the first 8 hours of exposure whereas vascular shutdown in vivo was observed within the first 4 hours. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-01 /pmc/articles/PMC2363703/ /pubmed/11161390 http://dx.doi.org/10.1054/bjoc.2000.1587 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Holwell, S E
Hill, B T
Bibby, M C
Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
title Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
title_full Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
title_fullStr Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
title_full_unstemmed Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
title_short Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
title_sort anti-vascular effects of vinflunine in the mac 15a transplantable adenocarcinoma model
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363703/
https://www.ncbi.nlm.nih.gov/pubmed/11161390
http://dx.doi.org/10.1054/bjoc.2000.1587
work_keys_str_mv AT holwellse antivasculareffectsofvinflunineinthemac15atransplantableadenocarcinomamodel
AT hillbt antivasculareffectsofvinflunineinthemac15atransplantableadenocarcinomamodel
AT bibbymc antivasculareffectsofvinflunineinthemac15atransplantableadenocarcinomamodel